Body system: Hemic and Lymphatic SystemsRegulation: 38 CFR § 4.117
Myelodysplastic syndromes (MDS) are a group of blood disorders where your bone marrow doesn't make enough healthy blood cells, leading to anemia, infections, and bleeding problems. The VA rates MDS from 30% to 100% based on how severe your treatment needs are. Higher ratings go to veterans who need stem cell transplants or chemotherapy (100%), while lower ratings cover those needing occasional blood transfusions or medications to help their body make more blood cells (30%).
Rating levels
- 100% — You qualify for this rating if your myelodysplastic syndrome (a blood disorder where your bone marrow doesn't make enough healthy blood cells) is severe enough that you need a stem cell transplant (replacing damaged blood-making cells with healthy ones from a donor or your own body) or you're receiving chemotherapy treatment (powerful medicines that fight the disease but often cause significant side effects).
- 60% — You qualify for this rating if you need 4 or more blood or platelet transfusions (receiving donated blood or blood components through an IV) within a 12-month period. You also qualify if you get infections serious enough that you have to be hospitalized 3 or more times in a 12-month period.
- 30% — To qualify for this rating, you need to have myelodysplastic syndrome that requires some regular medical treatment but isn't the most severe form. This includes needing 1 to 3 blood transfusions or platelet transfusions (receiving healthy blood cells or clotting cells through an IV) within a year, getting infections serious enough to put you in the hospital 1 or 2 times per year, or needing ongoing biologic therapy (specialized immune system medications) or ESA treatment (medications that help your body make more red blood cells) for up to 12 weeks per year.
- -1% — MDS has a meaningful risk of transformation to acute myeloid leukemia (AML), particularly in higher-risk IPSS or IPSS-R categories. If transformation occurs, the rating shifts from DC 7725 to DC 7703 (leukemia except CML), which uses its own 100%-during-active-disease-and-treatment + 6-month-post-treatment-exam framework. For MDS itself: if treatment is peripheral blood or bone marrow stem cell transplant (the only curative therapy for MDS), the 100% rating begins on the date of hospital admission and continues through transplant, engraftment, and recovery. If treatment is chemotherapy (hypomethylating agents such as azacitidine or decitabine; intensive AML-like induction in selected cases; lenalidomide for del(5q) MDS; venetoclax-based combinations), the 100% runs through the entire active chemotherapy period. Six months after hospital discharge (transplant) or six months after the last dose of chemotherapy, VA must schedule a mandatory examination. The exam decides whether to continue 100% or step down to one of the lower transfusion-based / infection-based tiers (60% / 30%) based on current treatment requirements and residuals. If there has been no recurrence, chronic residuals are rated separately under their own DCs — persistent cytopenias requiring ongoing transfusion or growth-factor support, infection susceptibility, secondary malignancy, graft-versus-host disease after allogeneic transplant, neuropathy or cardiotoxicity from chemotherapy, and infertility. If VA proposes to reduce the rating after the six-month exam, the protection of 38 CFR § 3.105(e) applies — VA must notify you 60 days before reduction with reasons and your right to a hearing.